Currently, CAR-T therapy has promising potential in the field of multiple myeloma treatment.

This article summarized the latest R&D progress of Methoxsalen, the Mechanism of Action for Methoxsalen, and the drug target R&D trends for Methoxsalen.

Sapience Therapeutics publicizes the demonstration of ST101 Clinical findings at the International Conference on Molecular Targets and Cancer Therapeutics held by AACR-NCI-EORTC in 2023.

This article summarized the latest R&D progress of Margetuximab, the Mechanism of Action for Margetuximab, and the drug target R&D trends for Margetuximab.

CYP2C9 is a member of the Cytochrome P450 superfamily of enzymes that primarily metabolize drugs in the human body.

This article summarized the latest R&D progress of Labetalol Hydrochloride, the Mechanism of Action for Labetalol Hydrochloride, and the drug target R&D trends for Labetalol Hydrochloride.

SpyBiotech has declared that they've submitted a clinical trial request to the U.K. MHRA for SPYVLP01 assessment.

This article summarized the latest R&D progress of Temsirolimus, the Mechanism of Action for Temsirolimus, and the drug target R&D trends for Temsirolimus.

Chimeric antigen receptor (CAR) T cell therapy, in which a patient’s own T lymphocytes are engineered to recognize and kill cancer cells, has achieved remarkable success in some hematological malignancies in preclinical and clinical trials.

This article summarized the latest R&D progress of Hydroxycarbamide, the Mechanism of Action for Hydroxycarbamide, and the drug target R&D trends for Hydroxycarbamide.

Merck has reported that the U.S. FDA is conducting a priority analysis on a fresh sBLA petitioning for authorization of KEYTRUDA, Merck’s anti-PD-1 treatment.

This article summarized the latest R&D progress of Gossypol, the Mechanism of Action for Gossypol, and the drug target R&D trends for Gossypol.